Frequently Asked Questions
See answers to the most commonly asked questions regarding MoveX
Movex is simple... and amazing... It is chondroitin 4 sulfate (C4S), suspended in sterile water with buffers to balance the PH. It is an all natural product that can dramatically reduce inflammation due to excessive exercise while increasing comfort and mobility. Chondroitin Sulfate is a large percentage of the molecules that make up tissues in the joints. Movex replenishes these structures with an all-natural version of this molecule, not a synthetic lab creation.
Movex is made in a sterile lab that meets the strictest requirements for product safety. The product is then sent to an independent pharmaceutical testing facility where each batch is tested for purity, contaminants, and PH. These independent lab tests are available for you to review. To receive the lab tests for your batch, please email email@example.com with the batch number off of the vial and we will email the testing results to you.
While it is considered a nutraceutical, Movex treats our product as if it were a pharmaceutical. Movex is made in a sterile laboratory. Each batch of product is then sent to an independent pharmaceutical testing facility to confirm dosage, quality, and safety. Each batch of product has a unique identification number and the independent lab testing results are available for you or your vet to review. You can count on Movex to protect your animals as if they were our own.
**An extensive clinical study was performed on equines regarding the affects of Chondroitin SuIfate injections. If you would like to receive a complete copy of this clinical study with all laboratory results, graphs, evaluations, discussions, conclusions, citations, and bibliography - please email firstname.lastname@example.org or call us at 813-448-2181. This was an independent study and was not conducted by Movex. The author of the study is properly cited below. This was not a drug study. This was a study on effectiveness of Chondroitin 4 Sulfate, which is a supplement and has not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, cure, or prevent any disease.
Summary of Study:
Materals and Methods:
A full clinical study was carried out on fifteen clinically healthy female equines between 5 and 10 years old. "Animals were divided at random into three groups of five animals each, named Group 1 to 3 respectively. Previous to the test and, in order to determine their condition, the animals were clinically and radiologcally examined. On the test day, the left carpus joint zone of all animals was depilated and then santitized and antisepticized. Immediately, each animal was immobilized in order to proceed to the extraction of 2 ml of synovial fluid, inoculating in the same operation .5ml of Adjuvant Complete of Feund (ACF) in the joint, to induce an aseptic arthritis. This operation was carried on in the fifteen animals taking part in the test."
The following treatments were carried on:
Group 1 (n=5): Application of 5 ml of Chondroitin Sulfate via intramuscular each 5 days (sterile solution at 12%, 120mg/ml).
Group 2 (n=5): Daily application of 10ml of Chondroitin Sulfate via oral, (solution at 25%, 250mg/ml)
Groupl 3 (n+5): No treatment (Control Group)
a. Articular Circumference
b. Strained Flexion
d. Analysis of the Synovial Fluid
e. Radiological Examination
f. Clinical Examination
g. Statistical Analysis
"...The increase of the articular circumference was significantly less in treated animals; this suggests a direct anti-inflammatory effect of chondroitin sulfate on the injury caused. On the other hand, the differences observed in the response to a strained flexion and the lameness degree, make us think of a significant analgesic effect, which contributes to a faster and better recovery of animals suffering articular injuries..."
"... The radiographic image makes evident the presence of a subchondral sclerosis plus loss of regular characteristics of the articular capsule present only in Control animals; this reveals a growth-inductive (chondrorepairing) effect of chondroitin sulfate on the cartilage injured by the ACF..."
"...The animals treated with CS via injectable showed a significant evolution 48 hours after the injury induction with respect to some of the evaluated parameters, which is consistent with the bioavailability of the product by this via, showing a plasmatic peak few hours after injection (18 hours). The response observed in the increase of the articular circumference was very good in 48 hours, improving the achievements of the group..."
"...From day 16 on, the evolution was similar to that observed in animals...and significantly better (p<0.05) than the one observed in Control animals..."
"...The obtained results are determinative and evidence the CS therapeutic value in the induced pathology,... Although differences are observed in the product behavior when administered by different vias, both proved to be effective and lead to normalize the articular condition after 30 days of treatment. The observed differences might be the basis for the elaboration of a possible therapeutic strategy based on the use of CS... in different moments of the articular pathology being treated. This shall determine the use of the products of a more or less quick effect, as well as the via of administration to be used..."
"... Considering what was previously mentioned and based principally in the experimental results of the present work, the discussion about the viability of the CS via oral or injectable seems to be out of place and inconvenient, in view of the numerous and overwhelming clinical and experimental results. Chondroitin Sulfate, in varied presentations is then an important therapeutic resource with which veterinarians count for the handling of articular problems..."
From: Effects of the Administration of Chondroitin Sulfate via Injectable and Oral in the Induced Equine Aseptic Arthritis,
Videla Dorna I. DVM(1) and Fuerrero R. C. DVM(2)
(1) Professor of Physiopathology, School of Veterinary Medicine, National University of the Center of Buenos Aires Province, Tandil, Province of Buenos Aires, Argentina. Technical Director, Syntex S.A. Prayones y Avellaneda, Luis Guillon, Buenos Aires, Argentina.
(2) Syntex Manager, Ayacucho, Ruta 74 Km 100, Pcia. de Buenos Aires, Argentina
**These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Below is what the experts have to say:
Polymer Design and Development
Christopher K. Arakawa, Cole A. DeForest, in Biology and Engineering of Stem Cell Niches, 2017
2.1.5 Chondroitin Sulfate
Chondroitin Sulfate (CS) is an unbranched glycosaminoglycan consisting of N-acetyl-d-galactosamine and d-glucuronic acid connected by β-1,3 and β-1,4 glycosidic linkages. During synthesis, the polysaccharide is sulfated in different locations along its more than 100 glycan chain and conjugated to serine residues on proteins. CS is a common constituent of cartilage and skin ECM and contributes to the viscoelastic nature of both tissues due to its high degree of hydration.19 Hybrid polymer conjugates and polymer–polymer mixtures utilizing CS as their main component have been employed in cartilage tissue engineering, cardiac tissue engineering, dermal engineering, drug release, and for intervertebral disk regeneration.5 On a cellular level, CS has been shown to upregulate the synthesis of hyaluronan, glucosamine, and type II collagen by both bovine and human chondrocytes while also shown to downregulate expression of enzymes responsible for cartilage ECM breakdown including MMP-1, MMP-3, MMP-13, and aggrecanase-2.20 Recent studies have also highlighted the ability of CS to reduce inflammation by inhibiting human leukocyte chemotaxis and phagocytosis.
21 These factors have made CS a particularly important tool in the design of tissue engineering solutions to osteoarthritis.
Maxime Dougados, in Osteoarthritis, 2007
Chondroitin sulfate is a macromolecule that contributes to (like hyaluronic acid) a framework for collagen formation. The rationale for use and the discussion concerning the available data for symptomatic efficacy are very similar to those discussed previously for glucosamine, except that the number of well-conducted placebo-controlled trials is much smaller with chondroitin sulfate.90
A recent double-blind placebo-controlled 2-year trial focused on the evaluation of both the symptomatic and structural effect of 800 mg chondroitin sulfate.101 This study failed to show a significant difference in terms of symptoms but did reveal a significant difference in terms of radiologic joint space progression (0.00 ± 0.53 versus 0.14 ± 0.61 mm in the chondroitin versus placebo group, respectively). As with glucosamine, chondroitin sulfate seems to be very safe.
Herbal and Nutritional Supplements for Painful Conditions
Andrea H. Zengion ND, MSAOM, Eric Yarnell ND, in Pain Procedures in Clinical Practice (Third Edition), 2011
Glucosamine Sulfate and Chondroitin Sulfate
Although they are not anodynes in the same sense as other remedies listed here, glucosamine sulfate and chondroitin sulfate are useful in the treatment of osteoarthritis pain because of their effect on joint structure. Glucosamine is a substrate for the glycosaminoglycans that comprise hyaluronic acid, a chief component of joint tissue.
Chondroitin plays a number of roles in connective tissue synthesis. It is itself a glycosaminoglycan and, when hydrated, it creates osmotic pressure that increases the compressive resistance of synovial cartilage. It also stimulates the production of collagen and proteoglycan and inhibits enzymatic destruction of the synovium.22,111
Osteoarthritis: Numerous studies have been performed to evaluate the efficacy of glucosamine and chondroitin administration for osteoarthritis treatment with mixed results, although this may be due to combining different forms of the agents, or to some studies’ use of less effective forms of glucosamine and/or chondroitin or products with poor standardization.53 Industry bias may also account for some of the discrepancy between studies, although it should also be noted that many of the studies not funded by industry sources examined glucosamine hydrochloride.112 According to a meta-analysis, glucosamine sulfate used alone relieved pain due to osteoarthritis and prevented disease progression.113 Glucosamine hydrochloride, although cheaper, is not effective for osteoarthritis.114 Conclusions derived from studies of one form cannot be extrapolated to apply to the other form, even though data for glucosamine sulfate are mixed.115
Chondroitin treatment reduced pain, swelling, and effusion, and maintained or improved joint space and serum osteocalcin levels. Glucosamine sulfate and chondroitin sulfate taken together decreased pain and joint effusion in moderate-to-severe arthritis pain, but results were inconsistent between studies.111,116
Dosage: 1500 mg glucosamine sulfate per day. 400 to 1200 mg chondroitin sulfate per day.
Caution/contraindication: Contraindication for glucosamine: shellfish or iodine allergy. Glucosamine may increase PT-INR when given with warfarin.117 Chondroitin may also increase the effects of anticoagulant therapies. Because of its structural similarities to heparin, some sources recommend that it be contraindicated in pregnanc
Give one shot IM (intramuscularly as directed) every 7 days for 4 weeks. This is the “loading dose” period. After the loading dose, most horses and/or dogs can be switched to a maintenance dose of once per month. Sport horses used in heavy competition can benefit from more frequent use of Movex, as often as every week for top-level performance
Just like any other injection, there is a slight risk of an injection site reaction. Occurance with Movex has been negligible. Movex has not been tested in pregnant animals.